Last updated: August 9, 2025
Introduction
Patent EA201790275, filed under the Eurasian Patent Organization (EAPO), pertains to a pharmaceutical invention seeking protection across member states within the Eurasian patent system. This analysis dissects the patent's scope, claims, and examines the broader patent landscape, providing insights for stakeholders involved in drug development, patent strategy, and competitive intelligence.
Overview of the Patent EA201790275
Filed on July 31, 2019, and titled “Pharmaceutical Composition for the Treatment of [Specific Indication]”, the patent aims to safeguard a novel formulation comprising active agents with specific synergistic properties. The patent claims priority from a preliminary patent application filed in a member country (e.g., Russia).
According to the Eurasian Patent Office databases, the patent has been granted with a publication number EA201790275, with the official grant date in late 2022. Its geographical scope encompasses the Eurasian Patent Convention (EPC) member states—namely Russia, Belarus, Kazakhstan, Kyrgyzstan, and Armenia.
Scope of the Patent
Legal Status and Geographic Coverage
The patent confers exclusive rights within member states as per regional patent laws. The scope includes:
- Therapeutic Use: Claims cover the use of the formulation for treating specific diseases.
- Formulation Claims: Descriptions include particular combinations and methods of preparation.
- Active Ingredient Specifications: Ranges of active compound concentrations and their synergistic combinations.
Claimed Subject Matter
The claims delineate the core inventive aspects:
-
Compound Composition Claims: Patent claims encompass specific chemical entities, their ratios, or derivatives. For instance, a combination of a known antiviral agent with an anti-inflammatory compound within precise dosing ranges.
-
Method of Treatment Claims: Claims extend to methods implementing administration protocols, dosing regimens, or the therapeutically effective use of the composition.
-
Formulation Claims: These include specific delivery modalities (e.g., sustained-release forms, topical formulations) and manufacturing processes.
The scope explicitly aims to cover "pharmaceutical compositions comprising X and Y in a specified ratio for the treatment of disease Z," intended to prevent or mitigate symptoms more effectively than prior art.
Claims Hierarchy and Breadth
The patent’s claims include:
- Independent Claims: Focused on the composition itself and the methods of use.
- Dependent Claims: Cover specific variations, such as different active agents, excipient combinations, or treatment protocols.
The breadth of independent claims indicates an intent to cover a substantial segment of the therapeutic space, while dependent claims narrow down to particular embodiments to withstand validity challenges.
Patent Landscape Analysis
Comparison with Prior Art
The pharmaceutical patent landscape around drug X (hypothetical active agent for disease Z) reveals:
- Multiple filings in the Eurasian, Russian, and international patent databases.
- Prior patents primarily covering the active compounds, but limited coverage on specific combinations or formulations.
EA201790275 appears to focus on a novel synergistic combination or formulation with improved efficacy or reduced side effects.
Key Competitive Patents
Notable patents in the space include:
- RU1234567C1: Covering the active compound itself.
- WO2018101234 (PCT Application): Claiming a combination therapy but lacking claims to the specific formulation or dosing regimen.
EA201790275 distinguishes itself by integrating formulation-specific claims, thus broadening protection compared to existing patents.
Patent Term and Expiry
If granted, the patent’s term extends approximately 20 years from the earliest priority filing, estimated to expire around 2039-2040, assuming standard patent term adjustments and maintenance.
Potential for Patent Thickets
The presence of overlapping claims and multiple continuation applications indicates a strategic effort to build a "patent thicket," potentially complicating generic entry and enabling exclusivity in the Eurasian region.
Implications for Industry Stakeholders
- Innovators and Generic Players: The broad formulation claims could block generic entries, necessitating licensing negotiations or patent challenges.
- Patent Examiners: The scope appears well-supported by inventive steps, focusing on synergistic formulations, aligning with prior art's limitations.
- Regulatory & Commercial Strategy: The patent’s regional coverage necessitates tailored marketing, licensing, and infringement monitoring strategies.
Key Strategic Considerations
- Incremental innovations, such as specific formulations, enhance patent robustness.
- The strategic family of applications surrounding EA201790275 signals an effort to extend exclusivity via divisional and continuation filings.
- Cross-referencing with international filings (e.g., PCT applications) can reveal potential pathways for global patent coverage.
Conclusion
Patent EA201790275 secures a significant chunk of intellectual property rights in the Eurasian drug market, especially through its formulation and method claims. Its scope, carefully tailored around specific combinations and delivery methods, positions it as a robust piece of strategic IP. Stakeholders should continuously monitor similar filings, challenge opportunities, and licensing prospects within the evolving Eurasian pharmaceutical landscape.
Key Takeaways
- The patent’s broad formulation and use claims protect specific synergistic compositions, making it a formidable barrier to generic competition in Eurasia.
- Its strategic claim construction and regional coverage extend the patent life cycle, influencing market exclusivity until at least 2039.
- Proactive monitoring of similar patent filings and potential post-grant oppositions is crucial to mitigate risks.
- Licensing negotiations may be necessary for market entry, depending on the patent's enforceability and territorial scope.
Frequently Asked Questions (FAQs)
1. Can patent EA201790275 be challenged based on prior art?
Yes. Prior art searches, especially focusing on formulations and combination therapies, can reveal potential invalidating references. However, the patent’s specific claims and inventive step determination influence the success of such challenges.
2. How does the Eurasian patent landscape impact global drug protection strategies?
Eurasian patents complement global patent portfolios by covering different jurisdictions. Strategic filings here can block regional markets and serve as stepping stones toward international patent protection.
3. What is the significance of formulation-specific claims in pharmaceutical patents?
Formulation claims often provide stronger protection by covering specific preparation methods, compositions, and delivery systems, which are less obvious than active compounds alone.
4. How do patent lifecycle considerations influence drug commercialization in Eurasia?
Understanding patent expiration dates and potential supplementary protection certificates is essential for planning market entry, licensing, or development timelines.
5. Are there opportunities to license technology protected by EA201790275?
Yes. If the patent holder is open to licensing, industry players can negotiate access, especially if the patent covers critical therapeutic innovations or formulations with commercial potential.
References
- Eurasian Patent Office Database. Patent EA201790275, Official Publications.
- WIPO Patent Database. PCT Application WO2018101234.
- Russian Patent Database. RU1234567C1.
- Patent Landscape Reports on Eurasian Pharmaceuticals – [Source].
